title: Cellular reprogramming: a new technology frontier in pharmaceutical research.
abstract: Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.
authors: Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts 02115, USA.
authors: Amy
authors: A
authors: Brock
authors: Hui-Tong
authors: HT
authors: Goh
authors: Binxia
authors: B
authors: Yang
authors: Yu
authors: Y
authors: Lu
authors: Hu
authors: H
authors: Li
authors: Yuin-Han
authors: YH
authors: Loh
mesh_terms: D000818:Animals; D054337:Cell Dedifferentiation / Q000502:physiology; D002454:Cell Differentiation / Q000502:physiology; D002460:Cell Line; D019070:Cell Lineage / Q000502:physiology; D065150:Cellular Reprogramming; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D064420:Drug-Related Side Effects and Adverse Reactions; D053595:Embryonic Stem Cells / Q000502:physiology; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000502:physiology*; D051379:Mice; D008954:Models, Biological; D004364:Pharmaceutical Preparations / Q000032:analysis*; D057285:Precision Medicine / Q000379:methods / Q000639:trends; D044968:Regenerative Medicine / Q000379:methods / Q000639:trends
chemical_list: D004364:Pharmaceutical Preparations